Boston Scientific Signs Investment Agreement with Chengdu High-Tech Zone to Strengthen Western China's Healthcare Ecosystem

Chengdu, Oct. 18, 2019 /PRNewswire/ -- On October 17, Mr. Mahongming, Global Chairman and Chief Executive Officer of Boston Scientific Corporation (NYSE: BSX),Michael Mahoney) The delegation arrived in Chengdu, Sichuan Province, for an inspection visit and met with key provincial and municipal government leaders, including Yin Li, Governor of Sichuan Province, and Luo Qiang, Mayor of Chengdu. On the same day, Boston Scientific signed an investment cooperation agreement with the Chengdu High-Tech Industrial Development Zone for the establishment of Boston Scientific’s “Second Headquarters” in China and an Innovation Center project. The initiative aims to leverage Sichuan Province’s high-quality medical resources and favorable business environment, combined with Boston Scientific’s leading expertise in minimally invasive interventions and professional education, to further strengthen the construction of a medical innovation ecosystem in Western China, enhance local medical technical services and disease management capabilities, and extend high-quality healthcare solutions to grassroots levels in Western China, benefiting communities across China and reaching global markets.

During this meeting, Sichuan Provincial Governor Yin Li first expressed high expectations for the strategic cooperation agreement signed previously between Boston Scientific Corporation and the Chengdu High-Tech Industrial Development Zone, themed “Rooted in Sichuan, Building China’s Second Headquarters,” to promote the high-quality development of Chengdu’s pharmaceutical and health industry. In the future, both parties will leverage their complementary advantages and engage in sincere collaboration in the healthcare sector. By utilizing AI technology and big data management, they aim to provide full-lifecycle health management for patients with chronic diseases. They will jointly establish an innovation center and apply 5G technology to build a remote medical education system, positioning Chengdu as a smart healthcare hub for Western China and even internationally. Furthermore, they will advance the “Belt and Road” initiative in medical technology by developing a standardized training system to export high-quality medical technologies and services to participating countries. Additionally, a Western China logistics center will be established to drive upstream and downstream enterprises to set up regional logistics platforms in Chengdu.

In recent years, Sichuan Province’s medical and health industry has demonstrated robust growth, fostering a thriving industrial cluster. Provincial and municipal governments in the region have set forth objectives centered on addressing critical needs, prioritizing the translation of research into practical applications, driving collaborative innovation, and promoting the industrialization of scientific achievements. By fully leveraging comparative advantages in pharmaceutical resources, science and technology, and industrial capabilities, these authorities have continuously strengthened industry-academia-research partnerships, improved the service system for transferring and commercializing biomedical innovations, accelerated the development of demonstration bases, and facilitated the translation and commercialization of technological breakthroughs in new drug development, thereby leading the growth of the biomedical industry in Western China and across the nation. Boston Scientific will leverage its strengths as a multinational corporation to engage more deeply in the development of Sichuan’s medical and health industry, injecting new vitality into the local innovation ecosystem.

Ma Hongming expressed gratitude to the Sichuan Provincial and Chengdu Municipal Governments for their long-standing support and assistance to Boston Scientific. As one of the most innovative medical technology companies, Boston Scientific remains committed to providing high-quality healthcare solutions for patients in China, thereby promoting the advancement and improvement of China’s medical technology. Leveraging this strategic collaboration as a starting point, Boston Scientific will continue to introduce globally leading health service concepts and innovative medical technologies, fully supporting Sichuan Province in building a modern healthcare industry system and establishing a world-class hub for the healthcare industry. Meanwhile, Boston Scientific will integrate its global professional educational resources to accelerate the enhancement of primary healthcare services in Sichuan Province, helping patients at the grassroots level better benefit from the achievements of medical innovation. This effort embodies the company’s commitment to “Innovating for Life” and contributes to the construction of a “Healthy China.”

About Boston Scientific

Boston Scientific is committed to innovating for life. We are dedicated to developing innovative medical solutions that improve the lives of patients worldwide. For four decades, Boston Scientific has been a leader in the global medical technology industry, offering a broad portfolio of high-performance medical solutions to meet the urgent therapeutic needs of patients and reduce healthcare costs. For more information, please visit our website:www.bostonscientific.cn

About Boston Scientific in Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently maintains branch offices in Beijing, Shanghai, Guangzhou, Chengdu, Hong Kong, and Taiwan. The company’s core business areas include interventional cardiology, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic interventions, peripheral and oncology interventions, urology and pelvic health, and respiratory products. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that is responsive to the needs of patients and healthcare providers, driven by innovative vitality, through the provision of high-quality medical products and services for prevention, diagnosis, and treatment. For more detailed information, please visit the company’s website:www.bostonscientific.cn

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can be identified by words such as “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” and similar expressions. These forward-looking statements are based on the Company’s views, assumptions, and estimates using currently available information and do not constitute guarantees of future events or performance. These forward-looking statements include statements regarding the Company’s expected net sales, U.S. GAAP operating and organic revenue growth rates, financial performance, business plans, and positioning for revenue and earnings growth.

If the underlying assumptions prove inaccurate, or if certain unforeseen risks or uncertainties materialize, actual results may differ materially from those expressed or implied in the forward-looking statements. In certain instances, these risks and uncertainties have already affected, and may in the future affect, the implementation of the Company’s business strategy, potentially causing actual outcomes to deviate from the expectations outlined in this press release. Accordingly, readers are cautioned not to place undue reliance on such forward-looking statements.

Risks and uncertainties that may cause differences include: future economic, political, competitive, reimbursement, and regulatory conditions; the introduction of new products and market acceptance of these products; product markets; anticipated pricing environments; anticipated procedure volumes; completion and integration of acquisitions; clinical trial results; demographic trends; intellectual property; litigation; financial market conditions; execution and effects of corporate restructuring plans; execution and effects of corporate business strategies, including our cost-saving measures, growth initiatives, and future business decisions by us and our competitors. New risks and uncertainties may also emerge at any time and are difficult to predict. All of these factors are difficult or even impossible to predict accurately, and many of them are beyond our control. For other significant risks and uncertainties that may affect the Company’s future operations, please refer to Item 1A “Risk Factors” in Part I of the latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission. The Company will also update risks and uncertainties in Item 1A “Risk Factors” in Part II of its quarterly reports on Form 10-Q that have been or will be filed. The Company does not intend and is under no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, including changes in expected developments or in the events, circumstances, or environment underlying such expectations, or changes in factors that may cause actual results to differ from those expressed in forward-looking statements. This cautionary statement applies to all forward-looking statements contained in this document.